Stockholders' Equity - Additional Information (Details) - USD ($)	1 Months Ended	3 Months Ended				4 Months Ended	9 Months Ended
	Apr. 30, 2024	Sep. 30, 2024	Jun. 30, 2024	Sep. 30, 2023	Jun. 30, 2023	Apr. 30, 2024	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	May 31, 2023	Jan. 31, 2023
Common Stock And Noncontrolling Interest In Subsidiaries [Line Items]
Dividends declared		$ 0					$ 0
Common stock, voting rights							Each share of common stock entitles the holder to one vote and to receive dividends when and if declared by the board of directors of the Company.
Preferred Stock, Par or Stated Value Per Share		$ 0.0001					$ 0.0001		$ 0.0001
Number of shares of common stock, percentage		9.99%					9.99%
Increase in number of shares of preferred stock, percentage		19.99%					19.99%
Shares issued		647,500					647,500		647,500
Shares sold/issued		58,141,130					58,141,130		42,900,083
Losses attributed to noncontrolling interests		$ 0		$ 0			$ (192,000)	$ (179,000)
Biotechnology Value Fund, L.P exchange agreement [Member]
Common Stock And Noncontrolling Interest In Subsidiaries [Line Items]
Newly designated Series A preferred stock											600,000
Preferred Stock, Par or Stated Value Per Share											$ 0.0001
Number of common stock exchange											6,500,000
In May 2023
Common Stock And Noncontrolling Interest In Subsidiaries [Line Items]
Offer and sell companys common stock										$ 125,000,000
2024 Private Placement
Common Stock And Noncontrolling Interest In Subsidiaries [Line Items]
Net Cash Proceeds from 2024 Private Placement	$ 262,700,000					$ 262,700,000
Offering costs	$ 17,300,000					$ 17,300,000
Shares sold/issued	14,400,000					14,400,000
Warrants Issued to Purchase Additional Common Shares	300,000					300,000
Common Stock
Common Stock And Noncontrolling Interest In Subsidiaries [Line Items]
Issuance of common stock and pre-funded warrants, Shares			14,421,070
Additional shares issued					3,310,000
Warrant
Common Stock And Noncontrolling Interest In Subsidiaries [Line Items]
Additional shares issued							300,000
Exercise price		$ 0.001					$ 0.001
At-the-Market Equity Offering Program | In May 2023
Common Stock And Noncontrolling Interest In Subsidiaries [Line Items]
Net proceeds							$ 38,400,000
Shares sold/issued		3,300,000					3,300,000
Treasury Stock, Common, Shares		85,600,000					85,600,000
MICA
Common Stock And Noncontrolling Interest In Subsidiaries [Line Items]
Losses attributed to noncontrolling interests							$ 4,400,000